Dr Roland Shu is a Principal Scientist at Cartherics. He joined the team in 2016 from Monash University where he previously worked on neural stem cell biology and Multiple Sclerosis therapy. At Cartherics, Roland focuses on designing molecular constructs, CRISPR gene editing and autologous cell product manufacturing. His long-term goal is to make Australia’s first CRISPR-Cas9 gene-modified CAR-T cells for cancer patients. He sees such products as ‘living drugs’.
Originally from China, Roland studied Biotechnology at Wuhan University where he received his Bachelor degree. He completed his PhD in molecular genetics at the Institute of Health Sciences of China’s Academy of Sciences and Shanghai Jiao Tong University. Before moving to Australia, Roland worked as a researcher for three years at GlaxoSmithKline’s Shanghai R&D centre.
Dr Nhu-Y Nguyen is a Research Fellow and Laboratory Manager at Cartherics. She received her PhD in 2011 from the University of Melbourne, focusing on the effects of targeting different signalling pathways involved in hematopoiesis. Following her PhD, Nhu-Y conducted her postdoctoral training at Monash University’s Australian Centre for Blood Diseases. There she devised a novel xenograft model for assessing new combination therapies for Acute Myeloid Leukaemia.
As a Laboratory Manager at Cartherics, Nhu-Y handles the day-to-day running of the Science Team. As a Research Fellow, she drives in vivo studies. She enjoys working with a team of like-minded and passionate individuals ‘who are as equally committed as I am to developing potential new cures for cancer’.
Dr Walid Azar is the newly appointed Chief Translation Officer heading the Translation Team at Cartherics. He holds extensive experience from a diverse scientific background, encompassing both academic research and the fast-paced biotechnology industry.
After achieving his PhD in cancer biology at the Murdoch Children’s Research Institute through the University of Melbourne, Walid pursued a postdoctoral fellowship at the Peter MacCallum Cancer Centre, under the supervision of Professor David Bowtell, where he led a NHMRC-funded project investigating the role of interleukin 6 (IL-6) in ovarian clear cell cancer. Walid’s research made a significant contribution towards the understanding of IL-6 signalling in ovarian clear cell cancer and identified potential therapeutic agents that could synergise with IL-6 pathway inhibition.
In 2016, Walid joined CSL R&D at the BIO21 Institute where he was responsible for providing molecular biology and genome editing support to the CSL R&D recombinant protein and gene therapy portfolio. Furthermore, he was responsible for successfully steering a new research project proposal through stage gate decisions to product development, with the possibility of clinical development.
Walid plays a major role in prioritising for development, discovery projects from the Cartherics research program and/ or from external collaborators, such as academic groups, private companies or medical institutes. His team’s role is to undertake the appropriate comprehensive preclinical studies, involving in vitro and animal functional models, to enable the clinical translation of the product for cancer therapy.
Dr Vera Evtimov is Cartherics’ Project Manager. After obtaining a Bachelor of Biotechnology (Hons) Vera continued her studies attaining a PhD at Monash University in the department of Biochemistry and Molecular Biology.
Vera first joined Cartherics as a Post-doctoral Research Fellow where her research focused on the production and characterisation of autologous CAR-T cell products. As Project Manager, Vera works closely with the scientific teams in planning, overseeing and leading the project through the research and development process.
Vera is passionate about improving the clinical outcomes of individuals diagnosed with debilitating diseases.
Dr Nick Boyd is a Biomaterials Engineer with a PhD and over 10 years experience specialising in tissue engineering, biological device R&D, regenerative medicine and nanotechnology. At Cartherics Nick focuses on generating an ‘off-the-shelf’ on-demand immunotherapy via stem cell sources.
With a deep background in immunology, stem cell differentiation and CAR-T cells, Nick helps drive the development and translation to the clinic of a novel natural killer (NK) cell-based immunotherapy derived from induced pluripotent stem cells. The work enables Nick to blend his passions for IP, entrepreneurship, business and laboratory research. Nick sees an exciting future for Cartherics and considers himself lucky to be part of the team investigating the impact their next-generation cellular therapies will have on patients suffering with ovarian cancer.
Dr Frederico Calhabeu has over 12 years research experience in the fields of stem cell biology and regenerative medicine, with a focus on the activation and self-renewal of adult stem cells in tissue injury and repair. Frederico was awarded his PhD in Cellular and Molecular Physiopathology at the Université Pierre et Marie Curie (Paris, France). He has held research positions at King’s College (London, England) as well as the Australian Regenerative Medicine Institute (Melbourne, Australia), where he gained extensive experience in primary cell culture, molecular biology and fluorescence microscopy. More recently, he took a particular interest in developing and helping translate innovative stem cell therapy projects to treat common muscle disorders.
In his role at Cartherics, Frederico is working on developing and bringing off-the-shelf NK cell therapies to cancer patients. Aside his passion for biomedical science, Frederico is passionate about football (the real one) and is a very much people person and always up for a chat.
Dr Madeline Cao received her MD in 2010 and practiced in Hematology at the Institute of Hematology & Blood Diseases Hospital in Tianjin, China. She then moved to Australia to expand her research interests on hematopoiesis, receiving her PhD degree in 2014 from the University of Melbourne. Afterwards, Madeline joined CSIRO as a postdoctoral Research Fellow in Professor Susie Nilsson’s group, working on a project to better understand the hematopoietic stem cell and its niche in order to identify important adhesive molecules and their roles in stem cell regulation. She joined Cartherics in 2019 as a Research Fellow where she works with IPSC-CAR-T/NK products that have great potential to kill tumor cells.
After several years investigating normal and malignant hematopoietic stem cells, Madeline has developed strong expertise in stem cell biology and has a huge passion for utilising stem cells to develop innovative therapeutic strategies to help patients fight cancer.
Deputy Laboratory Manager & Senior Research Officer
Senior Research Officer Maree Hammett has been with Cartherics since it was established in 2016 and helped set up the laboratories. She brings over a decade of experience in the university and industry sectors, developed after completing a Masters degree in immunology with Professor Tony Schwarer at Monash University and the Bone Marrow Transplant Unit at the Alfred Hospital.
At Cartherics, Maree works primarily with the autologous CAR-T team, testing & growing the different CARs and the development of the Method of Manufacture for clinical trials. Drawn to cancer research because her grandfather experienced Chronic Lymphoblastic Leukaemia, Maree seeks to boost the understanding of cancer detection, treatment and, hopefully, patient survival.
Kellie Cartledge is a Senior Research Officer at Cartherics. She joined the team in 2016. After completing her BSc in Biochemistry at Latrobe University then Honours in Biochemistry at the Australian National University, she worked at the Ludwig Institute of Cancer Research in the Molecular Biology Laboratory. Kellie then completed her MSc in Biopharmaceuticals at the University of New South Wales whilst working at CSIRO firstly in Health Science and then later in the Manufacturing Division. She was drawn to biological research as it is always evolving.
At Cartherics Kellie uses her expertise in cell culture, stem cell biology, T-cell biology and molecular biology in a range of projects, including the iPSC to T-cell and NK-cell projects. She finds the work challenging and at the cutting edge of immunology. “What we do will help people and society,” she says.
Philip Arandjelovic is a Research Fellow with Cartherics’ Translation team. Phil completed his PhD at the Walter and Eliza Hall Institute of Medical Research (Melbourne, Australia) where he used a model of persistent HIV infection to test the therapeutic potential of clinical compounds. This work is being translated into a clinical trial.
As part of the Translation team, Phil’s work at Cartherics builds on his expertise in immune cell biology and the application of in vivo models of disease in order to progress iPSC-derived effector cell programs through to manufacturing and development as immunotherapies for cancer.
Vingo Zhuang has been a Research Officer at Cartherics since the company was established in 2016. He is originally from Shenzhen in Southern China. Vingo graduated in 2000 from the Sun Yat-sen University School of Medicine in Guangzhou. In 2002 he moved to Melbourne in order to pursue his Masters at Monash University. Prior to joining Cartherics, Vingo worked at Monash University with Professor Sharon Ricardo in kidney research.
At Cartherics, Vingo’s main role until recently was to build CAR-T constructions and generate CAR-T viruses to infect T cells and produce early-stage CAR-T cells. He now produces the cells using CRISPR-Cas9.
Mat Tiedemann is a Research Officer within Cartherics’ Manufacturing and Development & Research teams. Mat is also undertaking a part-time PhD investigating differentiation of induced pluripotent stem cells (iPSCs) towards therapeutic cell types of the immune system. His work builds on expertise in gene editing and iPSC culture he developed as an undergraduate Research Assistant in Professor Jose Polo’s laboratory at the Australian Regenerative Medicine Institute.
Currently, Mat is involved in a number of projects, including gene editing of iPSCs using Cartherics’ Chimeric Antigen Receptor (CAR) construct, and the differentiation of resulting CAR-iPSCs throughout the hematopoietic lineage. The work is challenging because each cell line is unique, but Mat says the satisfaction gained by their successful differentiation is unparalleled.